How long does resistance to brigatinib last?

Brigatinib (Brigatinib) is an oral targeted therapy drug mainly used to treat non-small cell lung cancer, especially for patients with ALK fusion positive. It provides patients with new treatment opportunities by inhibiting the growth and spread of tumor cells. However, with the continued use of drugs, the problem of drug resistance has gradually become a focus of concern.

Regarding the resistance time of brigatinib, this is not a fixed period, but varies from person to person and is affected by many factors. On average, the duration of resistance is about about 1 year, but it can be shorter or longer. Some patients may develop resistance within 1 to 2 years after starting treatment, but others may remain sensitive to the drug for longer.

Clinical studies have found that approximately25% of patients develop disease progression within 12 months after receiving brigatinib treatment, which may be related to the development of drug resistance. However, the occurrence of drug resistance is not absolute and is affected by multiple factors such as the patient's own conditions, dosage, and tumor characteristics.

In order to prolong resistance, doctors and patients can take some measures. First, doctors will adjust the drug dosage or change drugs according to the patient's specific conditions in order to slow down the development of drug resistance. Secondly, patients should also receive regular evaluation and advice from doctors in order to detect and deal with drug resistance problems in a timely manner. In addition, maintaining good living habits and mentality and enhancing the body's immunity can also help delay the emergence of drug resistance.

It is worth noting that once drug resistance occurs, patients should seek medical treatment promptly and discuss the next treatment plan with the doctor. Medication combinations may need to be adjusted or other treatments tried to maintain disease stability and control.

In summary, the resistance time to brigatinib is not static, but is affected by a variety of factors. Through reasonable treatment strategies and patients' own efforts, the effectiveness of drugs can be prolonged and the quality of life improved.